大剂量胰岛素治疗钙通道阻滞剂中毒患者的血管扩张:氨氯地平与非二氢吡啶类药物的比较
该回顾性研究来自单一中毒中心,纳入2019-2021年接受大剂量胰岛素/葡萄糖治疗的钙通道阻滞剂中毒患者33例,其中氨氯地平中毒18例、非二氢吡啶类中毒15例(维拉帕米10例、地尔硫䓬5例)。氨氯地平组最大合并血管升压药中位数为3种(IQR 2-5,范围0-6),非二氢吡啶类组为2种(IQR 1-3,范围0-5;p=0.04),组间中位差值为1(95%CI 0-2)。氨氯地平组最大肾上腺素剂量中位数更高(0.31 mcg/kg/min vs 0.09 mcg/kg/min;p=0.03),解救性次甲基蓝使用更常见(7/18 [39%] vs 0;p=0.009)。作者认为这些差异提示氨氯地平中毒患者有更多血管扩张证据,需进一步研究大剂量胰岛素治疗氨氯地平中毒时是否发生协同血管扩张。
要点
- 氨氯地平中毒接受大剂量胰岛素治疗者最大合并血管升压药中位数为3种(IQR 2-5,范围0-6),非二氢吡啶类组为2种(IQR 1-3,范围0-5),p=0.04。
- 氨氯地平组最大肾上腺素剂量中位数为0.31 mcg/kg/min,高于非二氢吡啶类组的0.09 mcg/kg/min(p=0.03)。
- 氨氯地平组解救性次甲基蓝使用率为7/18(39%),非二氢吡啶类组为0(p=0.009)。
- 作者认为上述差异提示氨氯地平中毒患者有更多血管扩张证据,需进一步研究大剂量胰岛素治疗时是否发生协同血管扩张。
适用人群与场景
- 来自单一中毒中心2019-2021年通过通用代码「钙拮抗剂」识别、治疗「大剂量胰岛素/葡萄糖」为「已执行,无论是否推荐」的钙通道阻滞剂中毒患者。
- 纳入33例:氨氯地平中毒18例,非二氢吡啶类中毒15例(维拉帕米10例、地尔硫䓬5例)。
研究设计与关键结果
- 研究类型:回顾性研究,来自单一中毒中心,样本量33例(氨氯地平18例,非二氢吡啶类15例,其中维拉帕米10例、地尔硫䓬5例)。
- 主要终点:氨氯地平组最大合并血管升压药中位数为3种(IQR 2-5,范围0-6),非二氢吡啶类组为2种(IQR 1-3,范围0-5),p=0.04;组间中位差值为1(95%CI 0-2)。
- 关键次要终点:氨氯地平组最大肾上腺素剂量中位数为0.31 mcg/kg/min,非二氢吡啶类组为0.09 mcg/kg/min,p=0.03。
- 解救性次甲基蓝使用:氨氯地平组7/18(39%),非二氢吡啶类组0,p=0.009。
- 结论:氨氯地平中毒接受大剂量胰岛素治疗者较维拉帕米或地尔硫䓬中毒者需要更多血管升压药、更高剂量肾上腺素和更常接受解救性次甲基蓝,提示氨氯地平中毒患者有更多血管扩张证据。
证据类型、等级与局限
- 证据类型:回顾性研究,来自单一中毒中心。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,氨氯地平中毒接受大剂量胰岛素治疗的患者较维拉帕米或地尔硫䓬中毒者需要更多血管升压药、更高剂量肾上腺素和更常接受解救性次甲基蓝。
- 作者认为,需进一步研究大剂量胰岛素治疗氨氯地平中毒时是否发生协同血管扩张。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Background: High dose insulin (HDI), an inotrope and vasodilator, is a standard therapy for calcium channel blocker (CCB) poisoning. HDI causes vasodilation by stimulating endothelial nitric oxide synthase (eNOS). Most literature supporting HDI for CCB poisoning involves verapamil toxicity; however, amlodipine now causes more CCB poisonings. Unlike other CCBs, amlodipine stimulates eNOS and may cause synergistic vasodilation with HDI. The purpose of this study was to determine if amlodipine-poisoned patients treated with HDI had more evidence of vasodilation than similarly treated patients with non-dihydropyridine (non-DHP) poisoning.Methods: This was a retrospective study from a single poison center. Cases were identified via the generic code "Calcium Antagonists" in which the therapy "High Dose Insulin/Glucose" was "performed, whether or not recommended" from 2019-2021. Evidence of vasodilation was assessed via maximum number of vasopressor infusions per case, vasopressor doses, and use of rescue methylene blue to treat refractory vasoplegia.Results: Thirty-three patients were enrolled: 18 poisoned with amlodipine, 15 with non-DHPs (verapamil n = 10, diltiazem n = 5). The median number of maximum concomitant vasopressors in the amlodipine group was 3 (IQR: 2-5; range 0-6) and 2 in the non-DHP group (IQR: 1-3; range 0-5; p = 0.04); median difference in maximum concomitant vasopressors between groups was 1 (95% confidence interval: 0-2). Median maximum epinephrine dosing was higher in the amlodipine group (0.31 mcg/kg/min) compared to non-DHPs (0.09 mcg/kg/min; p = 0.03). Use of rescue methylene blue was more common in the amlodipine group (7/18 [39%]) than in the non-DHP group (0; p = 0.009).Conclusions: Amlodipine poisoned patients treated with HDI required more vasopressors, higher doses of epinephrine, and more often received rescue methylene blue than similarly treated patients with verapamil or diltiazem poisoning. These differences suggest amlodipine-poisoned patients had more evidence of vasodilation. Further study is warranted to determine if synergistic vasodilation occurs when HDI is used to treat amlodipine poisoning.
参考来源
- Cole JB, Lee SC, Prekker ME, et al. Vasodilation in patients with calcium channel blocker poisoning treated with high-dose insulin: a comparison of amlodipine versus non-dihydropyridines. Clin Toxicol (Phila). 2022. PMID: 36282196. doi:10.1080/15563650.2022.2131565
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。